Repligen Corporation (RGEN)
Market Cap | 7.04B |
Revenue (ttm) | 607.45M |
Net Income (ttm) | 14.84M |
Shares Out | 55.88M |
EPS (ttm) | 0.27 |
PE Ratio | 466.44 |
Forward PE | 77.06 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 2,107,744 |
Open | 136.00 |
Previous Close | 142.87 |
Day's Range | 125.02 - 138.26 |
52-Week Range | 110.45 - 211.13 |
Beta | 1.04 |
Analysts | Strong Buy |
Price Target | 199.11 (+58.1%) |
Earnings Date | Jul 31, 2024 |
About RGEN
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput... [Read more]
Financial Performance
In 2023, Repligen's revenue was $638.76 million, a decrease of -20.31% compared to the previous year's $801.54 million. Earnings were $41.58 million, a decrease of -77.64%.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for RGEN stock is "Strong Buy." The 12-month stock price forecast is $199.11, which is an increase of 58.10% from the latest price.
News
Repligen Announces CEO Transition Plan
Tony J. Hunt to Transition from Chief Executive Officer to Executive Chair, Olivier Loeillot Appointed to Role of President and Chief Executive Officer, Effective September 1, 2024 Tony J. Hunt to Tra...
Ecolab Life Sciences and Repligen Announce the Commercial Launch of DurA Cycle Affinity Resin for Large-Scale Biologic Manufacturing
ST. PAUL, Minn. & WALTHAM, Mass.--(BUSINESS WIRE)--Ecolab today announced that its Purolite resin business, together with Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioproc...
Repligen Corporation to Present at Upcoming June Investor Conferences
WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting ...
Repligen Corporation to Present at Upcoming May Investor Conferences
WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participati...
Repligen Reports First Quarter 2024 Financial Results
WALTHAM, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fi...
Repligen to Report First Quarter 2024 Financial Results
Webcast and Conference Call to Be Held Wednesday, May 1, 2024, at 8:30 a.m. ET Webcast and Conference Call to Be Held Wednesday, May 1, 2024, at 8:30 a.m. ET
Repligen Appoints Maggie A. Pax to Board of Directors
WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences industry executive Maggie A. Pax. This ...
Repligen Reports Fourth Quarter and Full Year 2023 Financial Results
WALTHAM, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its f...
Repligen to Report Fourth Quarter and Full Year 2023 Financial Results
Webcast and Conference Call to Be Held Wednesday, February 21, 2024, at 8:30 a.m. ET Webcast and Conference Call to Be Held Wednesday, February 21, 2024, at 8:30 a.m. ET
Repligen Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at th...
Repligen Announces Private Convertible Transaction of $600 Million Principal Amount of 1.00% Convertible Senior Notes Due 2028 Through Exchange and New Subscription Agreements
WALTHAM, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced that on December 6, 2023, it entered into privately negotiated exchange and/or subscription agreem...
UPDATE – Repligen Announces Publication of the Company's 2022 Sustainability Report
WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of...
Repligen Announces Publication of the Company's 2022 Sustainability Report
WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of...
Repligen Corporation to Present at Upcoming Investor Conferences
WALTHAM, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting...
Repligen Launches TangenX® SC as First-to-Market Holder-Free Self-Contained TFF Device
WALTHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of T...
Repligen Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance
WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its t...
The weight-loss drugs are coming for these companies — but here's why Coke, others, may be spared, says JPMorgan
Citing Vanda Research, the Wall Street Journal reports that the average individual-investor stock portfolio is up 150% since the start of 2014, versus around 140% for the S&P 500's SPX during the same...
Repligen to Report Third Quarter 2023 Financial Results
Webcast and Conference Call to Be Held Tuesday, October 31, 2023, at 8:30 a.m. ET Webcast and Conference Call to Be Held Tuesday, October 31, 2023, at 8:30 a.m. ET
Repligen Appoints Olivier Loeillot as President and Chief Commercial Officer
WALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has appointed 20+ ...
Repligen Announces Agreement to Acquire Fluid Management Innovator Metenova
WALTHAM, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into ...
Repligen Corporation to Present at Wells Fargo Healthcare Conference
WALTHAM, Mass., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presentin...
Sartorius and Repligen Corporation Launch Integrated System with Biostat STR® and XCell® ATF for Upstream Process Intensification
WALTHAM, Mass., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Sartorius and Repligen Corporation (NASDAQ:RGEN) today announced the launch of an integrated bioreactor system that incorporates Repligen XCell® ATF u...
Repligen Reports Second Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance
– Reports second quarter revenues of $159.2 million as reported, and base business revenues of $157.1 million, down 9% year-over-year
Repligen to Report Second Quarter 2023 Financial Results
Webcast and Conference Call to Be Held Wednesday, August 2, 2023, at 8:30 a.m. ET Webcast and Conference Call to Be Held Wednesday, August 2, 2023, at 8:30 a.m. ET
Repligen Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance
WALTHAM, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fi...